Dublin, Ireland-based Medtronic recently filed for FDA approval on its new artificial pancreas device and expects to introduce the product to the market in 2017, according to Bloomberg.
The MiniMed 670G incorporates a glucose sensor, insulin pump and patch with a small needle that injects insulin from the pump into the body.
The device reduces diabetes patients' daily maintenance requirements by automatically measuring blood sugar every five minutes and administering small doses of insulin when needed. The artificial pancreas also links up to a wireless smartphone-type device that shows blood sugar and insulin readings.
In a recent clinical trial involving 124 patients, the artificial pancreas technology consistently performed better than manual maintenance of the disease.
Medtronic expects the FDA to make a decision on the device within a year.
More articles on medical devices:
Medtronic acquires HeartWare for $1.1B
Medical device hacking on the rise
FDA approves new radiation therapy system